tiprankstipranks
Ocugen announces CHMP of EMA reviewed Phase 3 study design for OCU400
PremiumThe FlyOcugen announces CHMP of EMA reviewed Phase 3 study design for OCU400
15d ago
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
PremiumPress Releases
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
15d ago
Ocugen: FDA clears IND amendment to initiate Phase 3 clinical trial of OCU400
PremiumThe Fly
Ocugen: FDA clears IND amendment to initiate Phase 3 clinical trial of OCU400
18d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100